BREAKING NEWS
US economy adds just 12,000 jobs in October as hurricanes, strikes weigh
NasdaqGS - Delayed Quote USD
Vor Biopharma Inc. (VOR)
At close: October 31 at 4:00 PM EDT
Pre-Market: 9:21 AM EDT
Research Analysis
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Sep 2024) | Next Qtr. (Dec 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 9 | 9 | 9 | 9 |
| Avg. Estimate | -0.4 | -0.31 | -1.54 | -1.2 |
| Low Estimate | -0.44 | -0.42 | -1.7 | -1.71 |
| High Estimate | -0.36 | -0.2 | -1.33 | -0.53 |
| Year Ago EPS | -0.49 | -0.39 | -1.75 | -1.54 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Sep 2024) | Next Qtr. (Dec 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 6 | 6 | 7 | 6 |
| Avg. Estimate | -- | -- | -- | -- |
| Low Estimate | -- | -- | -- | -- |
| High Estimate | -- | -- | -- | -- |
| Year Ago Sales | -- | -- | -- | -- |
| Sales Growth (year/est) | -- | -- | -- | -- |
Earnings History
| CURRENCY IN USD | 9/30/2023 | 12/31/2023 | 3/31/2024 | 6/30/2024 |
|---|---|---|---|---|
| EPS Est. | -0.47 | -0.5 | -0.38 | -0.42 |
| EPS Actual | -0.49 | -0.39 | -0.45 | -0.41 |
| Difference | -0.02 | 0.11 | -0.07 | 0.01 |
| Surprise % | -4.30% | 22.00% | -18.40% | 2.40% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Sep 2024) | Next Qtr. (Dec 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.4 | -0.31 | -1.54 | -1.2 |
| 7 Days Ago | -0.4 | -0.31 | -1.54 | -1.2 |
| 30 Days Ago | -0.4 | -0.31 | -1.54 | -1.2 |
| 60 Days Ago | -0.4 | -0.31 | -1.54 | -1.21 |
| 90 Days Ago | -0.39 | -0.36 | -1.61 | -1.37 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Sep 2024) | Next Qtr. (Dec 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | VOR | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 18.40% | -- | -- | 5.10% |
| Next Qtr. | 20.50% | -- | -- | 11.80% |
| Current Year | 12.00% | -- | -- | 2.10% |
| Next Year | 22.10% | -- | -- | 12.30% |
| Next 5 Years (per annum) | -- | -- | -- | 11.68% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Upgrades & Downgrades
| Reiterates | JMP Securities: Market Outperform to Market Outperform | 9/6/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 9/6/2024 |
| Maintains | Barclays: Overweight to Overweight | 8/14/2024 |
| Reiterates | JMP Securities: Market Outperform to Market Outperform | 5/13/2024 |
| Reiterates | Oppenheimer: Outperform to Outperform | 5/13/2024 |
| Reiterates | Wedbush: Outperform to Outperform | 5/10/2024 |
Related Tickers
ELEV Elevation Oncology, Inc.
0.5743
-4.28%
CGEM Cullinan Therapeutics, Inc.
15.55
-4.13%
TNYA Tenaya Therapeutics, Inc.
1.9200
-6.34%
XLO Xilio Therapeutics, Inc.
1.2700
-7.30%
SANA Sana Biotechnology, Inc.
3.5000
-4.37%
UNCY Unicycive Therapeutics, Inc.
0.5350
+4.90%
RLYB Rallybio Corporation
1.0300
+0.98%
GOSS Gossamer Bio, Inc.
0.8780
-2.01%
IKNA Ikena Oncology, Inc.
1.7100
+0.59%
KPTI Karyopharm Therapeutics Inc.
0.9898
+17.81%